Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
Holding PRTA?
Track your performance easily
PRTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.52 - $55.89
Previous Close$16.59
Volume393.81K
Average Volume (3M)459.83K
Market Cap
$892.22M
Enterprise Value$340.23M
Total Cash (Recent Filing)$564.10M
Total Debt (Recent Filing)$12.12M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Oct 31, 2024EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding53,780,345
10 Day Avg. Volume913,793
30 Day Avg. Volume459,827
Standard Deviation0.26
R-Squared0.00101
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.53
Price to Sales (P/S)4.17
Price to Cash Flow (P/CF)14.20
P/FCF Ratio10.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit3.72
Enterprise Value/Ebitda4.74
Forecast
1Y Price Target
$64.00Price Target Upside283.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Prothena News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company remains on track to report multiple data points, including birtamimab’s Phase 3 AFFIRM-AL study in AL amyloidosis, prasinezumab’s Phase 2b PADOVA study in Parkinson’s, as well as coramitug's Phase 2 study in ATTR cardiomyopathy.
Financial PerformanceThe company ended 2Q24 with ~$565M of cash, and it increased YE24 cash guidance from ~$405M to ~$468M mainly due to the $80M payment from Bristol Myers Squibb.
LeadershipThe company announced the appointment of Chad Swanson, PhD as the new Chief Development Officer.
Bears Say
Clinical StudiesDepartures of chief medical officers of development stage companies historically does place more attention on ongoing clinical studies at those companies.
Leadership ChangeCMO departed to pursue opportunity in large pharma.
Market ExpectationsExpectations have come down significantly following the January updates as well as due to the slow ramp of Biogen’s Leqembi.
---
Ownership Overview
12.42% Insiders
28.58% Mutual Funds
0.09% Other Institutional Investors
50.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $15.52 and its highest was $55.89 in the past 12 months.
What is Prothena’s market cap?
Currently, no data Available
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Oct 31, 2024 which is in 17 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Aug 08, 2024. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of -$1.059 by $2.279.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -$1.17.
How many shares outstanding does Prothena have?
Prothena has 53,780,346 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of $1.22 in its last earnings report, beating expectations of -$1.059. Following the earnings report the stock price went up 4.421%.
Which hedge fund is a major shareholder of Prothena?
Among the largest hedge funds holding Prothena’s share is PRIMECAP Management Co. It holds Prothena’s shares valued at 753K.
---
Prothena Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.00 (283.46% Upside)
$64.00 (283.46% Upside)
Blogger Sentiment
Bullish
PRTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 41.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.71%
12-Months-Change
Fundamentals
Return on Equity
-8.75%
Trailing 12-Months
Asset Growth
-10.42%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2024
0:00 / 0:00
---
PRTA Stock 12 Month Forecast
Average Price Target
$64.00
▲(283.46% Upside)
Technical Analysis
Axsome Therapeutics
―
ACADIA Pharmaceuticals
―
Allogene Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+110.35%
reiterated a buy rating 15 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +110.35% per trade.
---